Ablynx extends agreement with Wyeth
Ablynx announced that its TNF-alpha partnership with Wyeth Pharmaceuticals has been extended for another year. Wyeth and Ablynx are collaborating to discover and develop novel Nanobody®-based therapeutics against TNF-alpha. Wyeth has exclusive rights to develop and commercialise the anti-TNF-alpha Nanobodies® developed under the collaboration.
As part of the collaboration Ablynx receives research funding and would be entitled to future milestone payments and royalties upon commercialisation.
Dr. Edwin Moses, CEO and Chairman of Ablynx, commented: "We are very pleased with the progress of our partnership with Wyeth, which has world class capabilities in the development and commercialisation of biologics. We look forward to continuing our collaboration for another year. This is an important partnership for Ablynx and we are delighted to continue our joint efforts to advance the TNF-alpha Nanobody®-based programme to the next stage."
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.